TL;DR
This study leverages incidental FDG-PET brain scans, routinely performed for cancer staging, to assess neuronal health. They found a surprisingly high prevalence of hypometabolism in Alzheimer's Disease (AD)-related brain regions, suggesting current diagnostic cutoffs might not be suitable for these "real-world" scans. This opens a new avenue for opportunistic AD screening within existing cancer imaging workflows.
What Problem Does This Paper Address?
Diagnosing Alzheimer's Disease (AD) often relies on specialized neuroimaging techniques like FDG-PET, which measure glucose metabolism in the brain as a proxy for neuronal activity. However, these scans are typically performed in dedicated neurology settings and can be costly and time-consuming. Meanwhile, many cancer patients undergo whole-body FDG-PET/CT scans, which incidentally capture brain images. The problem this paper addresses is whether these incidental brain scans, acquired under different protocols and for different primary indications, can be reliably used to detect signs of AD-related hypometabolism. The authors aim to determine the prevalence of such hypometabolism in a real-world cohort and explore its temporal changes, potentially unlocking a vast, underutilized data source for AD research and screening.
Methods
The researchers extracted demographic data and FDG-PET images from the electronic health records (EHR) of 1000 patients at Vanderbilt University Medical Center. They focused on brain images, performed quality control, and then calculated Standardized Uptake Value Ratios (SUVR) for established AD-related regions of interest (ROIs), including a meta-ROI, parietal lobes, and temporal lobes. They evaluated the prevalence of a "positive" AD meta-ROI (defined by SUVR ≤ 1.21) at initial staging and follow-up scans. To assess changes over time, they employed a linear mixed-effects model, accounting for subject-specific slopes and intercepts, and controlling for baseline age and sex.
Datasets
The study utilized data from the Vanderbilt University Medical Center's EHR. Specifically, they extracted FDG-PET images and demographic data from the most recently imaged 1000 patients. For their analysis, they focused on a subset of 396 patients aged 65 years and older. The paper does not introduce a new benchmark dataset but rather leverages existing clinical data.
Key Insights and Ideas
- Incidental Brain Scans as a Goldmine: The study highlights the potential of using routine cancer FDG-PET scans for opportunistic brain health assessment, particularly for AD. This could significantly expand the reach of neuroimaging for AD detection.
- High Prevalence of Hypometabolism: The observed prevalence of hypometabolism in AD-related regions (68.6% at initial staging) is remarkably higher than the expected clinical prevalence of AD (~10%). This suggests that standard AD diagnostic cutoffs might be too sensitive or not directly applicable to these incidentally acquired scans.
- Temporal Changes in Metabolism: The study observed a significant decrease in AD meta-ROI SUVR over time, which is consistent with expected age-related metabolic changes. This temporal analysis is crucial for understanding the natural progression of metabolic changes and differentiating them from disease-specific patterns.
- Need for New Cutoffs: The discrepancy between incidental findings and expected AD prevalence strongly suggests that new, validated cutoffs for AD meta-ROIs are needed for FDG-PET scans acquired during whole-body cancer imaging.
Key Results
- Out of 1000 patients, 396 patients aged 65 and older were included in the analysis.
- 272 patients (68.6%) showed a positive AD meta-ROI (SUVR ≤ 1.21) at their initial staging PET scan.
- This prevalence increased to 296 patients (74%) on follow-up scans.
- AD meta-ROI SUVR significantly decreased over time (β = -0.013/year, p = 1.63x10⁻⁴).
- Hypometabolism also decreased in the parietal lobe (β = -0.014/year, p = 2.57x10⁻⁵) and temporal lobe (β = -0.010/year, p = 1.68x10⁻⁴).
Limitations and Future Work
The authors acknowledge that the published cut-points for AD meta-ROIs may not be directly applicable to brain PET scans acquired during whole-body imaging. They suggest that different cut-points may be required. Future work includes evaluating the entire cohort of over 20,000 patients and conducting comparisons with age-matched control groups. Further research is needed to validate these findings and develop appropriate diagnostic criteria for incidental AD-related hypometabolism detected in cancer FDG-PET scans.
Summary updated